Interleukin-15 Overexpression Attenuates Muscle Fatigue Associated with Murine EO771 Mammary Tumors by Bohlen, Joseph F.
Graduate Theses, Dissertations, and Problem Reports 
2016 
Interleukin-15 Overexpression Attenuates Muscle Fatigue 
Associated with Murine EO771 Mammary Tumors 
Joseph F. Bohlen 
Follow this and additional works at: https://researchrepository.wvu.edu/etd 
Recommended Citation 
Bohlen, Joseph F., "Interleukin-15 Overexpression Attenuates Muscle Fatigue Associated with Murine 
EO771 Mammary Tumors" (2016). Graduate Theses, Dissertations, and Problem Reports. 5227. 
https://researchrepository.wvu.edu/etd/5227 
This Thesis is protected by copyright and/or related rights. It has been brought to you by the The Research 
Repository @ WVU with permission from the rights-holder(s). You are free to use this Thesis in any way that is 
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain 
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license 
in the record and/ or on the work itself. This Thesis has been accepted for inclusion in WVU Graduate Theses, 
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. 
For more information, please contact researchrepository@mail.wvu.edu. 
  
Interleukin-15 Overexpression Attenuates Muscle Fatigue Associated 
with Murine EO771 Mammary Tumors 
 
 
Joseph F Bohlen 
 
 
 
Thesis Submitted  
to the School of Medicine 
at West Virginia University  
 
in partial fulfillment of the requirements for the degree of 
 
Master of Science in  
Exercise Physiology  
 
 
 
 
 
 
   Emidio E. Pistilli, Ph.D., Chair 
Stephen E. Alway, Ph.D. 
I. Mark Olfert, Ph.D 
Linda Vona-Davis, Ph.D 
 
Department of Exercise Physiology  
 
 
 
 
Morgantown, West Virginia 
2016 
 
 
Keywords: Interleukin-15, Cancer Cachexia, Skeletal Muscle,  
Muscle Fatigue, Mitochondria 
 
Copyright 2016 Joseph F. Bohlen 
 
 
 
  
ABSTRACT 
Interleukin-15 Overexpression Attenuates Muscle Fatigue Associated with Murine  
EO771 Mammary Tumors 
 
Joseph F. Bohlen 
 
  
 Severe muscle wasting and muscle dysfunction (cachexia) are considered 
incurable complications associated with a wide variety of chronic diseases.  This loss of 
function and severe wasting causes an increase in fatigue in cancer patients, leading to 
reduced motivation for daily activities, further reducing prognosis for recovery in these 
patients leading to a severe increase in morbidity.  Recent work from our lab suggests 
Interleukin-15 (IL-15) induces a pro-oxidative state in the muscle, reducing fatigue and 
promoting a more oxidative phenotype.  One proposed mechanism behind this is the 
observation that IL-15  promotes mitochondrial biogenesis, lending more mitochondria 
for oxidative metabolic processes.    Therefore, we tested the hypothesis that orthotopic 
implantation of E0771 mammary tumor cells would induce greater muscle fatigue in 
tumor bearing mice and that muscle-specific IL-15 overexpression would attenuate this 
cancer-induced increase in muscle fatigability.  In our initial study performed in C57BL/6 
wild type mice, 4 weeks of E0771 mammary tumor growth induced a significant 
increase in muscle fatigue along with a significant reduction in mtDNA content, while 2 
weeks of growth had no effects on muscle function.  This was associated with lesser 
mRNA expression for IL-15 and IL-15Rα in the muscles of tumor bearing mice.  
Subsequently, we induced E0771 mammary tumors in muscle-specific IL15 over-
expressing mice and littermate control mice for 4 weeks.  While muscle fatigue was 
significantly greater in tumor-bearing littermate control mice compared to littermate 
control mice without tumors, muscle fatigue was attenuated in muscles from tumor-
bearing IL15 over-expressing mice compared to IL15TG mice without tumors.  These 
data highlight IL-15 a potential therapy for reducing fatigue in the weakened/cachectic 
state. Along with this, IL-15 has been well published with promoting Natural Killer (NK) 
cell cytotoxicity, increasing immunosurveillance and promoting overall T cell 
development.  This, combine with the pro-oxidative environment make IL-15 an ideal 
therapy for cancer cachexia.  Future studies can look at potential dosing requirements 
of IL-15 before moving on to clinical trials.   
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
Interleukin-15 Overexpression Attenuates Muscle 
Fatigue Associated with Murine EO771 Mammary 
Tumors 
 
Joseph F. Bohlen 
 
Division of Exercise Physiology, West Virginia University School of Medicine  
 
 
 
Chapter 1: Introduction               1 
Chapter 2: Background                                                                                     4 
2.1    Cancer Cachexia                                                                                        4 
2.2    Biomarkers and Indicators of Cancer Cachexia                                         5 
2.3    Immune function during Cancer Cachexia                                                 6 
2.4    IL-15s: A potential novel therapy for Cancer Cachexia                              8 
2.5    Background, Summary, Specific Aims                                                       9 
Chapter 3: The EO771 Adenocarcinoma Breast Cancer Cell Induces Cancer                                                                    
                  Cachexia at 4 Weeks in C57BL/6WT Mice                                   11 
3.1    Abstract                                                                                                    12 
3.2    Intro                                                                                                          14 
3.3    Methods                                                                                                    17 
3.4    Results                                                                                                      22 
3.5    Discussion                                                                                                 26 
3.6    References                                                                                                29 
3.7    Figures and legends                                                                                  31  
Chapter 4: Results: IL-15 Overexpression in EO771 Tumor Bearing Transgenic  
                  Mice                                                                                                 41 
4.1    Effects of IL-15 Overexpression on Muscle WT, CSA, CT and ½RT        38 
4.2    Effects of IL-15 Overexpression on Tetanic Force and Muscle Fatigue   45 
4.3    IVIS, Ultrasound, Tumor and Spleen cell isolation                                    50 
4.4   Tumor/Mouse weight, Muscle/BW                                                              50 
Chapter 5: General Discussion                                                                        54  
Chapter 6: Experimental Procedures                                                              61 
6.1   Mice                                                                                                             61 
6.2   EO771 Murine Breast Cancer Cells                                                            61 
6.3   Muscle Physiology on EDL and SOL Muscles                                            62 
6.4   Muscle Morphology                                                                                     63 
6.5   Mitochondrial DNA Content                                                                         64 
6.6   RNA Isolation for PCR                                                                                 64 
6.7   Spleen Cell Isolation                                                                                    65 
6.8   Tumor Dissociation                                                                                      66 
6.9   IVIS Imaging and Tumor Burden                                                                 66 
6.10 In Vevo Tumor Volume                                                                                66 
6.11  Data Collection and Statistics                                                                     67 
iv 
 
 
6.12  Animal Care                                                                                                 67 
Chapter 7: References                                                                                        68 
Chapter 8: Supplemental                                                                                    77 
 
1 
 
Interleukin-15 Overexpression Attenuates Muscle Fatigue 
Associated with Murine EO771 Mammary Tumors 
 
 
 
Joseph F. Bohlen 
Division of Exercise Physiology, West Virginia University School of Medicine  
 
Chapter 1. 
Introduction: 
Severe muscle wasting and muscle dysfunction (cachexia) are considered 
incurable complications associated with a wide variety of chronic diseases.  Cachexia 
significantly decreases the quality of life for cancer patients, more specifically; it leads to 
an overall poor prognosis for recovery and accounts for ~40-50% of cancer patient 
morbidity. (1) Cachexia is classified by a severe loss of body weight due to a significant 
loss of fat and muscle mass.  More pertinent to this study, however, is the muscular 
dysfunction (fatigue) that is associated with this disease.  Cachexia is considered a 
factor in determining cancer-related death, yet no direct experimental evidence has 
surfaced to solidify this hypothesis.  (2)  It has been well documented that standard 
nutritional approaches do not mediate muscle wasting in regards to cancer. (3,4)  In lieu 
of this, significant focus has shifted towards other strategies for reducing cachexia in 
cancer patients in order to improve prognosis.  
 
Cancer cachexia is believed to induce muscle wasting, along with muscle 
dysfunction eliciting significant fatigue and reduced motivation for daily activities.  This 
2 
 
fatigue is thought to be derived from alterations in skeletal muscle contractile machinery 
along with alterations in mitochondrial function.  Indeed, cachectic muscles show a shift 
in fatigue resistance, exhibiting a more glycolytic and fatigable phenotype in muscle 
fibers.  Recent data from our lab suggest IL15 might be an excellent therapy, with 
potential to reduce the outcomes of cancer cachexia. For example, recently our pilot 
studies have shown that IL-15 promotes a more oxidative/fatigue resistant phenotype. 
In addition, our IL15 transgenic overexpressor mice have shown marked increases in 
markers of mitochondrial biogenesis along with increases in cage activity due to higher 
levels of circulating IL15. In relation to muscle mass, IL-15 has been shown to cause 
skeletal fiber growth and stimulate myogenic differentiation (5,6).  IL-15 has also been 
shown to have a profound effect on the immune system, stimulating NK cell cytotoxicity, 
increasing immunosurveillance and protecting from tumor development (7).  Therefore, 
our central hypothesis is that overexpression of IL-15 will preserve muscle function, 
along with increasing the immuneosurveillance of T cells and NK cells, there by 
attenuating cancer cachexia and the subsequent severe tumor progression.  Currently, 
we have bred an IL15 skeletal muscle overexpressor mouse that we will inject with the 
EO771 adenocarcinoma cell line in order to examine the effects of IL15 overexpression 
on cancer cachexia.  We used these mice in conjunction with our background in muscle 
testing to address our hypothesis by completing the following aims. 
 
Aim 1: Determine the effects of IL15 skeletal muscle overexpression on muscle 
weight and muscle dysfunction seen in cancer cachexia. 
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Our working hypothesis is that IL 15 overexpression will preserve muscle function in the 
presence of cancer cachexia.  From our preliminary data, we know the EO771 breast 
cancer cell line causes increased muscle dysfunction along with significant muscle 
wasting.  We expect to see a preservation of muscle force and a resistance in fatigue in 
the presence of IL15 overexpression in tumor bearing mice.   
 
Aim 2: Determine the effects of IL15 skeletal muscle overexpression on cell 
populations in the spleen and infiltrating spleen cells in the solid tumor.   
Our working hypothesis is that IL15 overexpression will stimulate an increase 
percentage of Cytotoxic and Helper T cells and NK cells in both the spleen and tumor of 
the transgenic mouse.  Due to the ability of these cells to combat tumor formation and 
metastasis, we believe IL15 overexpression will reduce severity of tumor progression 
and symptoms experienced during cancer cachexia. 
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 Chapter 2. 
Background: 
2.1 
Cancer Cachexia 
 
Cancer is responsible for nearly 1,500 deaths every day, with fifty percent of 
these patients experiencing cachexia (8).  Cachexia is generalized as a weakness and 
wasting induced by a severe chronic illness.  The effects of cachexia are often 
exacerbated by the disease itself creating a self-sustaining loop.  One key component of 
cancer cachexia is the extreme depletion of skeletal muscle mass compounded with 
profound fat loss, along with severe fatigue in patients (2).  The main contributors to this 
disease are believed to be abnormal fluctuations in cytokines, hormones and tumor 
derived factors that alter the cellular environment (9).  Cancer cachexia is not limited to 
skeletal muscle alterations, this disease is also associated with neuroendocrine 
disorder, systemic inflammation, fat atrophy, and overall metabolic dysfunction (10).  
 Current treatment for cancer cachexia is multimodal in nature.  The basics 
include nutritional intervention along with supplemented exercise in order to stave off 
the wasting effects(11,12).  While these treatments do little to reverse the effects of 
cancer cachexia, they can potentially reduce the symptomology in some cases (13). 
The significant problem with traditional treatment methods for cancer (i.e. 
chemotherapy, radiotherapy) is the exacerbation of cachexia, further decreasing the 
prognosis of survival after treatment (14).    Recent drug trials in rats revealed a 
potential combination therapy that could alleviate the cachectic effects of cancer all 
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while reducing tumor burden (15).  The problem with this treatment is that these drugs 
could have severe adverse effects in human subjects.   Thus, it becomes critical to 
discover treatment options that attenuate these adverse reactions allowing other 
primary treatment to reduce tumor burden and move the cancer into remission.   
 
2.2 
Biomarkers and Indicators of Cancer Cachexia 
 
Markers of inflammation, skeletal muscle degradation markers and tumor derived 
compounds all show some degree of significance in regards to cancer cachexia and 
subsequent pathways of fatigue (16).  The main biomarkers we are concerned with in 
this instance are; Atrogin-1, Murf-1, TNFα, IL-6, IL-15 and IL-15rα.  TNFα has long been 
considered one of the more prominent indicators of cancer cachexia.  This 
proinflammatory cytokine is believed to play a role in growth and 
angiogenesis/metastasis of cancer cells (17).  More importantly high levels of TNFα 
have been linked with remodeling of stromal development along with being an 
endogenous tumor promoter (18).  There is evidence that suggests the pro-
inflammatory cytokine IL-6 also plays an important role in cancer cachexia (19).  While a 
main indicator of cachexia, IL-6 is believed to mediate the acute phase response 
involved with early infection and inflammation (20).  With progression of disease 
however, IL-6 has been shown to increase and inhibit cancer cell apoptosis and create 
drug resistance (21).   Atrogin-1 and Murf-1 have both been identified as muscle-
specific E3 ubiquitin ligases that are transcriptionally increased in the presence of 
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atrophy/atrophy-induced conditions (22).  These markers are enriched in skeletal 
muscle making them excellent markers of muscle atrophy in relation to cancer cachexia.  
IL-15, as previously mentioned, promotes mitochondrial biogenesis and fatigue resistant 
properties.  Along with this, IL-15 has a highly specific binding partner IL-15rα.  When 
bound together, they have the ability to act directly on skeletal muscle in a pro-oxidative 
manner (23).  Decreases in these two markers could possibly be a mechanistic link 
between the increases in fatigue found in cancer cachexia with the decrease in 
mitochondrial biogenesis.   
Importantly, cancer cachexia can be identified by decreases in bodyweight 
associated with severe loss of adipose tissue and muscle mass (9).  Measuring 
bodyweight is an easy and noninvasive way to gauge progression.  Measuring cross 
sectional area of a muscle section however, can provide a more comprehensive 
measurement of muscle wasting.  Indeed, cancer cachexia has been found to decrease 
cross sectional area with progression of disease, yielding more fibers that are smaller in 
size (24,25).  This can yield a muscle that fails to generate maximal amounts of force 
like their non-cachectic counterparts.   
 
2.3 
Immune Function during Cancer Cachexia 
 
Natural Killer (NK) cells express the ability to target specific cells without the 
need for antibody recognition (26).  In higher concentrations NK cells can identify and 
kill foreign pathogens increasing the productivity of the immune system (27).  Another 
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key component in immune function is the Helper and Cytotoxic T Cells.  Specifically, 
Helper T cells (CD4+) play a central role in regulating nearly all antigen-specific immune 
responses to invading pathogens (cancer cells)(28).  Just as important are the Cytotoxic 
T cells (CD8+), being able to induce tumor cell death upon direct recognition of peptide 
antigens (29).  Stemming from the alterations in skeletal muscle comes further 
dysfunction in the way of the immune response to cancer cachexia.  The alterations 
associated with cancer cachexia mostly affect innate responses to pathogens both in 
the tumor and systemically (30). A large issue with many cancers is the ability of the 
cells themselves so shed antigens or even promote T cell and NK cell lysis (31).  
Another mechanism blunting immune response is the tumors microenvironment 
preventing expansion/proliferation of helper and cytotoxic T cells, all while increasing 
the pro-inflammatory response causing eventual suppression of these cell types (32).   
 The problem with treating cancer with one specific drug is that it can alter a 
patient’s physiological homeostasis. Complications can arise with drugs that target the 
cancer cells or specific symptoms of cancer cachexia (anorexia) (33). One major 
adverse effect is immune suppression, which further inhibits the body’s response to 
invading pathogens increasing morbidity (34).  The inflammation response to cancer 
cachexia mainly involves the previously mentioned pro-inflammatory cytokines IL-6 and 
TNFα.  TNFα has been shown to promote adhesion of free floating tumor cells along 
with promoting malignancy (35,36).  IL-6 shows similarities, promoting both cancer cell 
growth, along with resistance to therapy (37).  With these alterations to immune 
function, along with the increase in fatigue from cancer cachexia, an ideal treatment is 
needed that can alleviate these symptoms without exacerbating the cancer itself.   
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2.4 
IL-15s Role in Cancer Cachexia 
 
The primary goal of this research is to ascertain the ability of IL-15 to attenuate 
muscle fatigue and maintain immune function during progression of cancer.  If 
confirmed IL-15 therapy would complement other treatments in the reduction of cancer, 
increasing longevity and survival rates among patients. IL-15 is a recently discovered 
four-helix bundle cytokine (38).  Skeletal muscle is considered to have the largest pool 
of IL-15 mRNA, with increases in systemic IL-15 exhibiting a pro-oxidative environment 
(39,40).  Therefore, we proposed the use of an IL-15 overexpressor mouse in order to 
test the effects of IL-15 during a cachectic state.    IL-15 has been shown to promote a 
pro-oxidative phenotype in skeletal muscle creating fatigue resistance along with 
increasing markers for mitochondrial biogenesis (41). With the increased mitochondria 
biogenesis, muscle fatigue would be reduced. This proposed shift in mitochondria 
volume could potentially alleviate any fatigue induced by cancer cachexia.   
Il-15 is believed to promote maturation in NK cells and T cells, allowing for an 
increased immune response in association with invading pathogens (42).    Along with 
this, IL-15 would promote greater immunesurveillance and encourage infiltration of the 
primary tumor, reducing overall tumor burden (42-44). Understanding how IL-15 
overexpression effects cancer cachexia in a mouse model is the first step in identifying 
its effectiveness as a supplemental therapy. We expect that our research will identify IL-
15 as a mitigator of cancer cachexia, reducing overall severity and associated 
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symptomology.  Upon the conclusion of the proposed study, we will have a feasible idea 
of the next steps needed in order to apply this to a clinical environment.   
 
2.5 
Background summary, aims, and hypothesis  
 
 The symptomology of cancer cachexia brings about multiple complications that 
can lead to early morbidity.  The primary goal of this research is to solidify a treatment 
method which attenuates cachexia.  Once established, we will than look into clinical 
dosing aspects and potential combination therapy to than reduce tumor burden and 
more importantly reduce the rate of muscle fatigue.  We expect that our research will 
identify IL-15 as a mitigator of cancer cachexia, reducing rate of muscle fatigue and 
increasing the immune response to the tumor.  With increasing circulating levels of IL-
15 comes an increase in biomarkers of mitochondrial biogenesis (i.e. PGC-1α, 
PPARα/δ).  Through transcriptional activation and increased signaling comes a 
subsequent increase in the amount of mitochondria per cross sectional-area.  This 
creates a more oxidative fiber type in skeletal muscle, promoting a fatigue resistant 
phenotype.  IL-15 is already well-published in promoting immunosurveillance through 
proliferative effects on NK cells and cytotoxic CD8 T cells.    
 With this in mind this project has two specific aims: first, determine the effects of 
IL-15 overexpression on reducing the rate of muscle fatigue, and second, to determine 
the effects of IL-15 overexpression on NK cell and T cell populations in the spleen and 
tumor of injected mice.  For these two aims, we injected IL-15 skeletal muscle 
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overepressor mice and litter controls with the EO771 adenocarcinoma cell line.  The 
EO771 cell line is ER-positive and immunosuppressive in nature.   After 4 weeks all 
tissues and muscle were collected and analyzed.  It was hypothesized that IL-15 
skeletal muscle overexpression would attenuate the increased rate of muscle fatigue 
experienced in cachectic tumor burdened mice when compared to littermate controls.  
Furthermore, it was hypothesized that IL-15 skeletal muscle overexpression would 
increase NK cell and T cell count in the spleen and tumor when compared to littermate 
controls.   
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The EO771 Adenocarcinoma Breast Cancer Cell Induces Cancer Cachexia at 4 
Weeks in C57BL/6WT Mice. 
 
Severe muscle wasting and muscle dysfunction (cachexia) are considered incurable 
complications associated with a wide variety of chronic diseases.  Cachexia significantly 
decreases the quality of life for cancer patients; more specifically, it leads to an overall 
poor prognosis for recovery and accounts for ~40-50% of cancer patient morbidity.  
Cachexia is classified by a severe loss of body weight due to a complete loss of fat and, 
more pertinent to this study, profound loss of skeletal muscle mass.   Breast cancer is 
considered the most frequently diagnosed cancer in females accounting for 14% of 
cancer deaths with ~27% of these patients experiencing cachexia.  Therefore, we 
hypothesize that mice with severe cancer cachexia following 4 week cell injection 
(EO771) will show decreases in force production along with decreased fatigue 
resistance.  PURPOSE: To determine whether the EO771 cell line induces a solid 
tumor and subsequently causes cancer cachexia altering muscle weight and function.  
METHODS: C57BL/6WT female mice were split into three groups consisting of an un-
injected control group (n=8), a 2 week post injection group (n=5) and a 4 week non-
ulcerated tumor (n=4) and ulcerated tumor post injection group (n=6). Isometric force 
and fatigue properties were determined in EDL and soleus muscles ex vivo while all 
other muscles and organs were dissected and weighted.  RNA was isolated from tibialis 
anterior muscles and reverse transcribed for semi quantitative PCR.  DNA was isolated 
in order to look at mitochondrial DNA content using RT-PCR.  RESULTS:  4WK 
ulcerated EDL muscles showed a significant decrease in tetanus force (CON 214.0 ± 
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23.26 nM vs. 4WK ulcerated 149.9 ± 42.58 nM,  p<0.0001) with a shift in the force 
frequency curve, along with significant loss of muscle mass compared to both the CON 
and 2WK time point(CON 10.58 ± 1.152 mg vs. 4WK ulcerated 7.325 ± 0.9621mg, 
p<0.0001).  4WK mice also showed increases in markers for inflammation and muscle 
atrophy  CONCLUSION: The results of this study suggest that the EO771 cell line does 
in fact induce cachexia.  The decrease in muscle weight, along with an increase in 
fatigue coincides with the symptomology of cancer cachexia.  Furthermore, the 
increases in inflammatory markers, atrophy markers highlight the physiological 
alterations taking place in this disease.  Methods of therapy can now be applied to this 
particular cell line when considering attenuation of cancer cachexia. 
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INTRODUCTION 
 Severe muscle wasting (cachexia) is considered an incurable complication 
associated with a wide variety of chronic diseases.  Cachexia significantly decreases 
the quality of life for cancer patients; more specifically, it leads to an overall poor 
prognosis for recovery and accounts for ~40-50% of cancer patient morbidity(1).  
Cachexia is classified by a severe loss of body weight due to a complete loss of fat and, 
more pertinent to this study, profound loss of skeletal muscle mass.    The 
symptomology of this disease includes fatigue, anorexia and abnormal biochemistry, in 
turn altering several metabolic pathways in tissues and organs.  (2,3) Generalized 
circulating factors such as tumor derived compounds, inflammatory cytokines, acute 
phase proteins and skeletal muscle degradation markers all play significant roles 
respectively. (3) Specifically, TNF α and IL – 6 have been documented to increase 
progressively along with the severity of cancer (4). Markers of acute muscle atrophy 
such as, MAFbx/Atrogin-1 and Murf1 have also shown upregulation in multiple models 
of cancer (5). The downstream effect of these factors is usually a loss of myofibrillar 
proteins in muscle cells resulting in muscle weakness and fatigue.  This is exacerbated 
by the increase in apoptosis compounded with impaired regeneration capabilities seen 
in cancer patients(6).   Interestingly cachexia has shown selective atrophy in fast 
glycolytic fibers, associated with increases in proinflammatory cytokines (7). 
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One possible mechanism behind the cachectic fatigue resides in alterations in 
mitochondrial function.  Considered multi-functional organelles, mitochondria provide a 
majority of the ATP in cells along with participating in a plethora of signaling cascades, 
including apoptosis.   In a Lewis Lung Carcinoma model, mitochondrial ATP synthesis 
was shown to decrease suggesting mitochondrial dysfunction as the potential cause for 
muscular fatigue (8). Circulating factors produced by cancer cells have also shown to 
alter electron transport chain  (ETC) activity, reduce basal respiration, along with 
potentially creating a self-amplifying loop of oxidative stress (9).One implication behind 
this is the upregulation of reactive oxygen species (ROS), signaling the induction of 
tumorigenesis and metastasis (10).  UCP3, the predominant uncoupling protein in 
skeletal muscle, has also shown marked alterations.   Increases in amount and activity 
of UCP3 show reductions in proton gradient across the inner mitochondrial membrane. 
This increases energy expenditure via the dissipation of energy as heat (11).  
Breast cancer is considered the most frequently diagnosed cancer in females 
accounting for 14% of cancer deaths (12).  Traditional interventions do little to attenuate 
the progressive wasting associated with cancer cachexia.  There is a general decrease 
in food intake, compounded with a state of hypermetabolsim that yields standard 
nutritional approaches futile (13).  Therefore, it becomes pertinent to identify ideal 
mouse models of cachexia in order to test feasible methods of treatment that do not 
exacerbate these wasting symptoms.   In this study we examined the effect of the 
EO771 breast cancer cell line on initiation of muscle wasting and dysfunction in 
C57BL/6 WT mice.   The EO771 breast cancer cell line is aggressive and proliferates 
rapidly.  In this case we wanted to show solid tumor development in immunocompetent 
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mice looking at metastases, muscle wasting/dysfunction, tumor burden and metabolic 
alterations following 2 and 4-week tumor bearing periods.  We hypothesize that mice 
with severe cancer cachexia will show decreases in force production along with 
decreased fatigue resistance.  Concluding this study, we plan to identify this as an ideal 
model for use when studying breast cancer cachexia looking for potential therapies to 
attenuate the downstream alterations.   
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METHODS  
Mice 
C57BL6WT mice were purchased from The Jackson Laboratory (n=23) and randomly 
assigned to a control group (Control; n=8), mice that were euthanized following 2 weeks 
of tumor growth (2WK, n=5), and mice that were euthanized following 4 weeks of tumor 
growth (4WK, n=10).  The 4WK group was subsequently divided into mice that 
developed an ulcerated tumor (4WK-UT; n=6) and mice that developed a non-ulcerated 
tumor (4WK-NUT; n=4).  Mice were housed in the animal vivarium at West Virginia 
University at 22°C under a 12:12-h light-dark cycle and received food and water ab 
libitum.  All animal experiments were approved by the Institutional Animal Care and Use 
Committee at West Virginia University. 
 
E0771 Murine Breast Cancer Cells 
The E0771 cell line used in these studies was kindly provided by Dr. Metheny-Barlow 
from Wake Forest University.  E0771 cells were cultured using aseptic technique and 
maintained under standard mammalian culture conditions (37ºC, 99% humidity, 5% 
CO2).  Cells were maintained in high glucose DMEM supplemented with 10% FBS to 
maintain active proliferation.  Cells were passed via trypsinization using 0.25% 
trypsin/EDTA in Hanks buffered saline solution (Gibco).   Cells were grown until ~90% 
confluent at which time they were prepped for injection.  Cells were trypsinized and 
resuspended in sterile PBS.   A cell count was performed yielding 1 million cells per 
100µL injection into the 4th nipple (mammary fat pad) of female C57BL/6 WT mice.   
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In vivo tumor bioluminescence and volume measurements. 
Mice were injected with luciferase-expressing EO771 breast cancer cells and imaged 
weekly for quantitative evaluation of tumor growth and dissemination. About 150 mg/kg 
D-luciferin (Caliper Life Sciences) was injected into the peritoneum.  Images were 
obtained using the IVIS Lumina-II Imaging  System and Living Image-4.0 software  (14). 
 
Ex vivo muscle physiological analysis 
Muscle contractile properties were examined in the fast extensor digitorum longus 
(EDL) and slow soleus muscles of experimental mice.  Mice were deeply anesthetized 
by breathing 4% isoflurane delivered through a nose cone at a flow rate of 1 l/min. 
Muscles were removed with both proximal and distal tendons intact, and nylon sutures 
were attached to the tendons. Muscles were transferred to an oxygenated tissue bath 
that contained Ringer solution (100 mM NaCl, 4.7 mM KCl, 3.4 mM CaCl2, 1.2 mM 
KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, and 5.5 mM D-glucose) maintained at 22°C. 
Ex vivo muscle stimulation was performed using a commercially available muscle 
physiology system (Aurora Scientific, Ontario, CA). Muscle length was adjusted to 
obtain the maximal twitch response (i.e., Lo). Three twitch contractions were performed 
all separated by 2 min. Parameters analyzed from isometric contractions included peak 
isometric twitch force (Pt), time to peak twitch tension (TPT), half-relaxation time of 
twitch contraction (½ RT), and peak isometric tetanic force (Po).  Isometric tetanic 
contractions were stimulated in muscles at a stimulation frequency of 120 Hz for EDL 
muscles and 80 Hz for soleus muscles, a stimulation current of 20 V, and lasting 500 
ms.   Following isometric contractions, the muscles remained in oxygenated Ringer’s for 
19 
 
5 minutes prior to the repeated-stimulation fatigue protocol. Muscle fatigue was 
analyzed using a repeated stimulation protocol lasting 6 min and consisting of repeated 
40-Hz tetanic trains that occurred once every second and lasted 330 ms.  The fatigue 
index was calculated as the difference in force from the first contraction and every tenth 
subsequent contraction, and plotted as a fatigue curve. (Burke1973, Pistilli 2011) 
Muscles were flash frozen in isopentane cooled to the temperature of liquid nitrogen 
and stored at –80°C. Muscle CSA was calculated by dividing the muscle mass by the 
product of the muscle density coefficient (1.06 g • cm3), muscle Lo, and the fiber length 
coefficient (EDL: 0.45, soleus: 0.69). This whole muscle CSA value was used to 
calculate specific force (i.e., absolute force mN • muscle CSA–1) (Brooks 1988, Lynch 
2001) 
 
Muscle Histology and Morphology 
Serial frozen sections (10 μm thick) of EDL and SOL muscles were obtained using a 
cryostat at −21°C and placed onto glass slides (Superfrost/Plus, Fisher Scientific). 
Sections were stained with Alexa Flour® 488-conjugate AffiniPure Goat Anti-Rabbit IgG 
(Jackson ImmunoResearch Labratories, INC) and ANTI-LAMININ Affinity Isolated 
Antigen Specific Antibody(SIGMA-ALDRICH®) and then mounted with 4’,6-diamidino-2-
phenylindole (DAPI) mounting medium (Vector Laboratories, Burlingham, CA).  
 
Mitochondrial DNA content 
Total DNA (genomic and mitochondrial) was extracted from tibialis anterior (TA) 
muscles from female mice using a DNeasy Blood and Tissue kit (Qiagen, Valencia, CA) 
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and quantified using a Nano-Drop spectrophotometer (ThermoScientific, Waltham, MA). 
TaqMan primers for mitochondrial DNA-encoded cytochrome-c oxidase subunit II 
(COXII) and nuclear-encoded 18S ribosomal RNA were used to perform real-time 
qPCR. The wells of a 96-well optical reaction plate were loaded with a 20-μl volume 
consisting of TaqMan 10X PCR Master Mix, a primer mix for either the mitochondrial-
encoded gene or the nuclear-encoded gene, and DNA diluted to a concentration of 5 
ng/μl. Each DNA sample was analyzed in pairs and amplified in an Applied Biosystems 
7900HT Fast Real-Time PCR system. The cycle threshold (CT) values of the 
mitochondrial-encoded COXII gene and the nuclear-encoded 18S gene in muscles 
C57BL/6 WT mice were used to quantify the fold change using the ΔΔCT calculation 
(Livak 2001). 
 
mRNA Analysis 
Total RNA was isolated using Trizol reagent (Life Technologies, Grand Island, NY), as 
previously described (15). RNA quantity and quality were assessed using a Nano-Drop 
2000 spectrophotometer (ThermoScientific, Waltham, MA); the 260/280 ratio for all 
samples used was between 1.8 and 2.1. Two micrograms of total RNA was reverse 
transcribed to make cDNA using a high-capacity reverse transcription kit according to 
manufacturer's instructions (Life Technologies, Grand Island, NY).  Amplification was 
performed in a reaction consisting of 8.5 μl nuclease-free H2O, 12.5 μl 2X Taq-Pro Red 
Complete 1.5 mM MgCl2 master mix (Denville Scientific, Metuchen, NJ), 1.0 μl forward 
primer, 1.0 μl reverse primer, and 2 μl of DNA template to make a 25 μl total reaction 
volume. Primers were constructed from published sequences.   Primer pairs for IL-15, 
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IL-15 rα, IL-6, TNFα, Murf1 and Atrogin-1 were coamplified with primer pairs for 18S 
(Ambion, Austin, TX). The number of PCR cycles was determined in preliminary 
experiments to ensure analyses were done in the linear range of amplification. 
Following amplification, each reaction was visualized following gel electrophoresis in 1% 
(wt/vol) agarose gels stained with ethidium bromide.  PCR bands were quantified using 
the ImageJ software program (http://rsbweb.nih.gov/ij/). Signals for the gene of interest 
were normalized to the bands for 18S that were amplified in the same reaction. 
Spleen Cell Isolation 
Spleens were dissected from mice and spleen cell populations were isolated by creating 
a cell suspension in 1.5% FBS RPMI.  Cells were then passed through a 70µm filter into 
a new tube.  Red blood cells were lysed by adding 4 mL of fresh Tris-NH4Cl at room 
temperature and letting stand for 3 minutes.  Tris- NH4Cl was inhibited with 5 mL of 10% 
FBS RPMI and two washing steps performed using 1.5% FBS RPMI.  A cell count was 
performed yielding 1 million cells per vial.  Samples were than stored in 0.5% 
paraformaldehyde until being re-suspended in FACS buffer for flow cytometry analysis.   
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RESULTS 
In vivo tumor burden.  One million E0771 tumor cells were implanted into the 
mammary fat pads of female wild type C57BL/6 mice and cell bioluminescence and 
tumor volume were monitored weekly.  As seen in Figure 1A, representative images 
display a progressive increase in cell bioluminescence and tumor size through four 
weeks.   
 
E0771 tumor induced alterations in body and muscle mass.  The body mass of 
female C57BL6 following 2 weeks of tumor growth was not significantly different from 
control non-tumor bearing mice.  However, the body mass of mice following 4 weeks of 
tumor growth was 28% less than both control and 2 week mice.  The masses of 
individual skeletal muscles of the lower limb all displayed a similar response pattern.  
The normalized muscle masses of muscles from female C57BL6 mice following 2 
weeks of tumor growth was not significantly different from control non-tumor bearing 
mice (Figure 8).  The normalized muscle masses in mice following 4 weeks of tumor 
growth were significantly less than control mice and mice following 2 weeks of tumor 
growth (Figure 8).  The absolute and normalized mass of the spleen was greater in 
mice following 4 weeks of tumor growth compared to control mice and mice following 2 
weeks of tumor growth. (Figure 8E) 
 
Fatigue properties.  Muscle fatigue was analyzed using a repeated stimulation 
protocol, with the fatigue index calculated as the percent difference of each contraction 
from the initial contraction of the protocol.  When the fatigue index was plotted, a clear 
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pattern emerged with respect to the duration of tumor exposure.  The fatigue index 
curve of EDL muscles from mice exposed to 4 weeks of tumor growth was shifted to the 
left during the initial 20-70s of the protocol compared to the fatigue index of EDL 
muscles from control mice and mice exposed to 2 weeks of tumor growth, indicating a 
significant loss of force with repeated contractions during this timeframe.  There were no 
differences in the fatigue index curve of EDL muscles from control mice compared to 
mice exposed to 2 weeks of tumor growth (Figure 4A).  The total area under the curve 
(AUC) was calculated for each fatigue curve.  Supporting the fatigue curves, there was 
a significantly lower AUC when comparing the fatigue curves of EDL muscles from mice 
exposed to 4 weeks of tumor growth to control mice.  In the soleus muscle, there were 
no significant differences between the groups in the fatigue index (Figure 4B) or the 
AUC.  The mtDNA content, as assessed by qPCR, showed a statistical significance for 
a reduction in muscles from mice exposed to 4 weeks of tumor growth compared to 
muscles from control mice, suggesting the duration of tumor growth affected 
mitochondrial density in skeletal muscles (Figure 4C). 
 
Isometric force production.   The CT of EDL muscles was significantly longer in mice 
following 4 weeks of tumor growth compared to control mice (Figure 2C).  The 1/2RT of 
EDL muscles was also longer in mice following 4 weeks of tumor growth compared to 
control mice (Figure 2D).  Absolute maximal tetanus force of EDL muscles was 
significantly lower in mice following 4 weeks of tumor growth in the ulcerated group 
compared to control, 2WK and 4WK non-ulcerated mice (Figure 3C).  Absolute tetanus 
force was also significantly lesser in EDL muscles from 4 week ulcerated tumor mice at 
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stimulation frequencies of 80, 100, 120, and 150Hz (Figure 3A).  When the force-
frequency relationship was expressed as force normalized to maximal force, there was 
a significant leftward shift of the relationship, such that force was significantly different in 
4 week mice at stimulation frequencies of 1, 5, 10, and 25Hz (Figure 3B).   
 There were no differences in the CT or 1/2RT of twitch contractions in SOL 
muscles (Figures 2G, H).  Absolute maximal tetanus force was significantly lower in 
4WK mice compared to control and 2 week mice (Figure 3F).  Absolute tetanus force 
was also significantly lesser in SOL muscles from 4WK mice at stimulation frequencies 
of 50, 80, and 100Hz (Figure 3D).  There were no differences in the force-frequency 
relationship when expressed as force normalized to maximal force (Figure 4F).   
 
Single Fiber Area  Analyzing cross sectional area (CSA) following laminin staining we 
saw a significant shift in the 2WK and both 4WK groups to the left in the EDL muscles, 
indicating a greater percentage of smaller fibers in these muscles in response to cancer.  
(Figure 6 A, B) No shift was seen on the SOL muscles for any groups (Figure 6 C, D) 
 
mRNA Expression Control mice showed the highest levels of IL-15 and IL15rα.  In 
regards to IL-15 there was a linear decrease in skeletal muscle expression, with the 4 
week groups expressing the lowest amount (Figure 5C).  IL-15 rα showed a significant 
decrease in 2week and both 4 week groups when compared to control mice (Figure 
5F).  IL-6 expression increased linearly with progression of cancer, with the 4 week 
ulcerated group having significantly high levels (Figure 5 B).  While TNF α did show 
marked increase, levels in the 4 week ulcerated group did not reach significance(Figure 
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5 E).  Atrogin 1and Murf 1 showed a significant increase in the 4 week ulcerated group 
when compared to all other groups (Figure 5 A, B).   
IVIS Imaging   Tumor progression increased linearly from week to week.  These data 
were confirmed with caliper measurements (0.5236 x W2 x L) looking at the volume of 
the tumor (Figure 7B).  The photon flux from the tumor is proportional to the number of 
light emitting cells and the signal can be measured to monitor tumor growth and 
development (Lim 2009) (Figure 7C).  Flux numbers began an exponential increase at 
the 3 and 4WK time points verifying the increase in tumor growth.  At the 4WK time 
point there was a contrast between large solid tumors and smaller necrotic tumors 
containing ulcerations (Figure 7 A, B).  These data indicate a differentiation in response 
to the Eo771 cell line.   
 
Spleen Cell Percent No significant differences were seen between T cell or NK cell 
populations (Figure 9 A, B).  A t-test between the CON and 2WK groups revealed a 
significant decrease in T cell % at the 2WK time point.   
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DISCUSSION  
The profound muscle wasting from cancer cachexia is associated with muscle 
weakness and reduced strength (16).  Many attribute muscle wasting as the main 
contributor to the decrease in strength and muscle weakness, some studies suggest 
additional factors that contribute to the alterations in excitation-contraction coupling and 
development of force (17).  Inflammatory cytokines secreted by and in response to 
tumors have been shown to directly induce signaling pathways that have been shown to 
upregulate enzymes that induce skeletal muscle protein turnover (18). Specifically, in 
this model there is a significant increase in IL-6 in the 4WK Ulcerated group, one of the 
main inflammatory markers in cancer cachexia.  While there was no significant 
difference in TNF α in skeletal muscle, there was a greater increase in the 4WK 
Ulcerated group.  These data indicate the 4WK Ulcerated group having a more severe 
response to the cancer and a subsequent increase in cachexia.  Significant increases in 
Atrogin1 and Murf1 along with decreases in fiber area and single fiber CSA in all cancer 
groups in the EDL muscle coincide with muscle atrophy seen in cancer cachexia.  While 
not entirely similar to muscular dystrophy loss of dystrophin protein is associated with 
increases in MuRF1/Atrogin1activity increasing myofibrillar protein breakdown (19). 
Furthermore, muscle weights for the Gastrocnemius, Tibialus Anterior, Quadriceps, 
Plantaris, EDL and SOL showed significant decrease in the 4-week time point, even 
when normalized to overall body mass, indicating this cancer cell line having a 
cachectic effect on muscle mass.  Indeed, mice in the 4WK Ulcerated group 
experienced severe cachexia illustrated by weight loss measured after tumor removal.   
EDL muscles showed increased CT and 1/2RT indicating alterations in calcium handling 
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with the contractile machinery, further contributing to muscle dysfunction.  EDL force 
frequency expressed as force normalized to maximal forces expressed a significant 
leftward shift in both 4WK groups indicating these muscles are producing lower force.  
Furthermore, the EDL of 4WK mice had a significant drop in force from 30-70 
contractions during the fatigue protocol indicating a significant increase in fatigue in 
these mice.   This shift further exemplifies the contractility alterations seen in many 
cancer cell lines that exhibit a cachectic/dysfunctional effect (17).     Il- 15rα has been 
implicated as being a binding partner for IL-15, increasing biological activity and half-life 
of IL-15 (20).  In our model we show significant decreases in IL-15 and IL-15rα mRNA 
levels in all cancer groups.  Furthermore, decreases in IL-15 and IL-15rα can be 
associated with a decreased rate of mitochondrial biogenesis contributing to the 
increase in fatigue seen in the EDL muscles at 4WK time point.  This decrease yields 
potentially less functional mitochondria decreasing the overall oxidative capacity of the 
muscle (8, 9, 10).   Indeed, the mtDNA assay showed significant decreases in genomic 
DNA in both 4WK time points coinciding with our fatigue data.   While SOL muscles did 
experience a decrease in max tetanic force at both 4WK time points and a significant 
decrease in weight at the 4WK Ulcerated time point, all other physiological parameters 
were unchanged.  This is supported by previous work showing preservation in a more 
oxidative muscle in cancer cachexia (7).  Spleen cell data showed do differences 
between groups in T cell% or NK cell%.  This perhaps could be due to a small sample 
size or the immunosuppressive nature of this cell line at later stages of development 
(21). 
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These data highlight a clear separation in progression and severity of cancer 
cachexia.  There was a clear delineation at the 4WK time point leading to two different 
phenotypic responses to the E0771 cell line which can be representative of ~40-50% of 
cancer patients (1).  Our 4WK Ulcerated mice showed significant increases in 
transcriptional markers of inflammation, atrophy along with a significant decrease in 
tetanic force combined with an increased rate of fatigue associated with a decrease in 
mtDNA content.  While our 4WK Non-Ulcerated group did exhibit similarities in fatigue 
and mtDNA content, we saw no significant differences in our markers for atrophy and 
inflammation along with no differences in maximal tetanic force.   In conclusion we 
establish that the EO771 adenocarcinoma cell line produces a solid tumor increasing in 
size with progression of disease.  At the 4WK time point mice exhibited signs and 
symptoms of cancer cachexia supported by the decrease in force output, increased rate 
of muscle fatigue and decrease in muscle mass.  These data indicate the EO771 cell 
line is ideal for use in determining the effects of certain therapies on cancer cachexia.   
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Figure 2 
EDL and SOL WT, CSA, CT and ½ RT:  A, B. EDL weight (mg) and CSA (mm
2
) showed significant decreases in the 4 
WK Ulcerated Tumor group.  E, F.  EDL CT and ½ RT showed significant increases hinting at alterations in Calcium 
handling during contractions.  C, D.  SOL weight (mg) and CSA (mm2) showed significant decreases in the 4 WK 
Ulcerated Tumor group.  G, F.  No differences were seen in SOL CT and ½ RT.  CON (n=8), 2WK (n=5), 4WK Non 
(n=4), 4WK Ulc (n=5). *=P<0.05, **=P<0.005, ***=P<0.0001 
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Figure 3 
EDL and SOL Force Frequency and Tetanus. A, B. EDL Absolute and Relative Force Frequency showed a shift similar to 
a oxidative muscle phenotype in both 4WK groups indicating a decrease in  absolute force output and force output 
relative to maximal contraction showing EDL muscle producing higher forces at earlier stimulation frequencies.   E. 
4WK Ulcerated Tumor EDL Max Tetanus showed a significant decrease in force (mN) when compared to other groups.  
C, D.  Both 4WK groups showed a shift in the Absolute Force Frequency however, Relative Force Frequency showed no 
differences.  F.  SOL  Max Tetanus showed a significant decrease in both 4WK tumor groups.    CON (n=8), 2WK (n=5), 
4WK Non (n=4), 4WK Ulc (n=5). *=P<0.05, **=P<0.005, ***=P<0.0001 
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Figure 4 
EDL and SOL Fatigue curve, Mitochondria DNA Content.  A. Both 4WK Tumor bearing groups showed a significant 
increase in fatigue shifting down and to the left.  2WK mice remain un-affected when compared to CON  B.  No 
Differences were found in SOL Fatigue across all groups.  C. Mitochondrial DNA Content showed a significant 
reduction in content in both 4WK groups, coinciding with the shift in the fatigue curve in A.  CON (n=8), 2WK (n=5), 
4WK Non (n=4), 4WK Ulc (n=5). *=P<0.05, **=P<0.005, ***=P<0.0001 
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Figure 5 
RNA Isolation from Tibialus Anterior muscles:  All groups represented as Con/2WK/4WK NUT/4WK UT  A. PCR 
amplification of Atrogin1 revealed significantly higher levels in the 4WK UT group compared to CON.  B.  PCR 
amplification of IL-6 revealed significantly higher levels in the 4WK UT group compared to CON  C.  PCR amplification 
of IL-15 showed significant decreases in both 4WK groups when compared to CON and 2WK groups.  D. PCR 
amplification of Murf1 showed significant increase in the 4WK UT group when compared to CON.  E. PCR amplification 
of TNF-α showed a modest trend towards increasing in the 4WK UT group, however significance was not reached.  F.   
PCR amplification of IL-15 rα showed significant decreases in all 3 tumor bearing groups when compared to CON.  CON 
(n=8), 2WK (n=5), 4WK Non (n=4), 4WK Ulc (n=5). *=P<0.05, **=P<0.005, ***=P<0.0001 
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Figure 6 
 EDL and SOL Muscle Fiber Area:  A. From Left to Right CON, 2WK, 4WK Non-Ulcerated, 4WK Ulcerated.  B.  EDL Muscles 
show a shift in the Fiber Number with progression of cancer, with a larger culmination of smaller fibers in the 4WK 
Ulcerated group.  C. The EDL Cumulative Frequency shows a shift to the right indicating similar results as B., D. From Left 
to Right CON, 2WK, 4WK Non-Ulcerated, 4WK Ulcerated.  E, F. Fiber number and Cumulative Frequency show no real 
differences between groups.  CON (n=4), 2WK (n=4), 4WK Non (n=4), 4WK Ulcerated (n=4) 
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Figure 7 
Tumor Weight/Volume and Body Weight: A Tumor Weight of the 3 tumor bearing groups (mg).  4WK Non-ulcerated Tumors 
weight the most and was significantly greater then both  2WK and 4WK Ulcerated.  B.  Tumor Volume (mm
3
) in 3 tumor groups.  
Similar to weight, 4WK Non-ulcerated tumors had the largest volume compared to 2WK and 4WK ulcerated.  C  Tumor Flux (x10
8
)  
in 3 tumor groups.  Both 4WK groups had a similar trend of a larger tumor flux.  D.  Body mass after removal of the tumor (mg).  
4WK Ulcerated Tumor mice had a significant decrease in body mass.  E % Difference in Body Mass.  4WK Ulcerated Mice had the 
largest difference in body mass when comparing pre-injection of cells and post-dissection CON (n=8), 2WK (n=5), 4WK Non (n=4), 
4WK Ulc (n=5). *=P<0.05, **=P<0.005, ***=P<0.0001 
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Figure 8 Muscle and Spleen Normalized BW: A. Tibialus Anterior weight normalized to body weight.  B. 
Gastrocnemius weight normalized to body weight.  C. Plantaris weight normalized to body weight.  D. 
Quadriceps muscle normalized to body weight.  E. Spleen weight normalized to body weight.  CON (n=8), 
2WK (n=5), 4WK Non (n=4), 4WK Ulc (n=5). *=P<0.05, **=P<0.005, ***=P<0.0001 
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Figure 9 Spleen T Cell and NK Cell %:  A., B. No differences were seen between groups with regards to T Cell or 
NK Cell. C.  T Cell comparison of CON and 2WK time points shows a significant decrease at 2 weeks.  D. No 
differences in CON vs 2WK time points.  .  CON (n=8), 2WK (n=5), 4WK Non (n=4), 4WK Ulc (n=5). *=P<0.05 
 
40 
 
Figure 10  EDL/SOL Weight and CSA: A., C. CON EDL/SOL Weights with a significant decrease with the CON 
Non-Ulcerated group. B., D. CON EDL/SOL CSA with a significant decrease with the CON Non-Ulcerated 
group E., G. TG EDL/SOL Weights showing a significant decrease in both the TG Non-Ulcerated and 
Ulcerated groups.  F.  EDL CSA show a significant decrease in both the TG Non-Ulcerated and Ulcerated 
groups.  H.  No statistical differences were seen between groups for SOL CSA. CON (n=8), CON Non (n=8), 
CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001 
 
 
Chapter 4 
Results: IL-15 Overexpression in Transgenic Mice 
4.1 
Effects of IL-15 Skeletal Muscle Overexpression on Muscle WT, CSA, CT and ½RT  
 In order to test the effects of cancer cachexia on skeletal muscle function we 
purchased the IL-15 Skeletal Muscle overexpressor mouse from Jackson Laboratory.  
These mice have previously been characterized by Quinn (52).  In brief, the HSA-
IL2SP-IL15 construct uses a Human alpha-skeletal actin promoter region, along with an 
IL-2 signal peptide region combine with Murine IL-15 cDNA.  This construct yields 
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Figure 11 EDL/SOL CT and ½ RT for CON and TG:  A. EDL CT showed no differences between groups. B.  EDL ½ 
RT showed significant increases in the CON Non-Ulcerated group.  C., D. SOL CT and ½ RT showed not 
differences in the CON groups.  E., F.  EDL muscles showed a significant increase in CT and ½ RT in both the TG 
Non-Ulcerated and TG Ulcerated Group.  G., H.  SOL muscles showed no differences between groups in both CT 
and ½ RT.  CON (n=8), CON Non (n=8), CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, 
**=P<0.005, ***=P<0.0001 
 
significant increases in skeletal muscle IL-15 mRNA and protein content, as well as 
increased serum levels of IL-15. (52)   Mice were bred yielding both IL-15 skeletal 
muscle overexpressors (IL-15 TG) and littermate controls (CON).   EO771 cells were 
cultured and injected into the fat pad adjacent to the 4th nipple.  For comparison 
purposes mice were grouped into 6 groups; CON (n=8, un-injected), CON Non-
Ulcerated (n=8, injected), CON Ulcerated (n=2, injected), TG (n=7, un-injected),  TG 
Non-Ulcerated (n=7, injected) and TG Ulcerated (n=4, injected).   
 With regards to the CON groups, EDL and SOL weights was shown to 
 
42 
 
Figure 12 EDL Relative and Absolute Force Frequency:  A. EDL Absolute Force frequency shows a significant reduction in tetanus 
force in the  50-150Hz stimulation frequency’s for the CON Non-Ulcerated and CON Ulcerated.  B.  EDL Relative Force Frequency 
shows no significant difference between groups.  C.  EDL Maximal Tetanus was significantly reduced in the CON Non-Ulcerated 
group.  D. EDL Absolute Force Frequency showed a significant reduction in the 100-150Hz stimulation frequency’s for the TG Non-
Ulcerated and TG Ulcerated groups.  E.  Relative Force Frequency showed a small shift in the 25-50Hz stimulation frequency’s for 
the TG Non-Ulcerated and TG Ulcerated groups.  F.  No statistical differences were seen for maximal tetanus force for the TG 
groups.  CON (n=8), CON Non (n=8), CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001 
 
significantly decrease with the CON Non-Ulcerated Tumor group (Figure 10A, 10C).  
While the CON Ulcerated groups did not reach significance, it is important to note this 
group had 2 mice perhaps showing why significance was not reached in this or any of 
the subsequent groups.    CSA for both EDL and SOL showed a significant decrease 
with the CON Non-Ulcerated Tumor group (Figure 10B, 10D).  The TG group showed a 
significant decrease in the EDL and SOL weights in both the TG Non-Ulcerated and 
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Figure 13 SOL Relative and Absolute Force Frequency:  A. Sol Absolute Force Frequency showed a 
significant decrease in both the CON Non-Ulcerated and CON Ulcerated group compared to the CON 
group at the 25Hz-100Hz stimulation frequency.  B. Relative Force Frequency show a significant shift at 
the 100Hz stimulation frequency in both the CON Non-Ulcerated and CON Ulcerated groups.  C. SOL 
Maximal Tetanus force showed a significant decrease in the CON Ulcerated group when compared to the 
CON group.  D. SOL Absolute Force Frequency showed a significant decrease in both the TG Non-
Ulcerated and TG Ulcerated groups at the 80Hz-100Hz stimulation frequency.  E. SOL Relative Force 
Frequency a significant shift at the 100Hz stimulation in both the TG Non-Ulcerated and TG Ulcerated 
groups.  F.  SOL Maximal Tetanus Force showed no statistical difference between groups. CON (n=8), 
CON Non (n=8), 4WK Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, 
***=P<0.0001 
 
Ulcerated groups (Figure 10E, 10G).  EDL CSA was shown to significantly decrease in 
the TG Non-Ulcerated and Ulcerated groups (Figure 10F) with no effect on SOL CSA 
(Figure 10H).  Overall we see a similar trend with muscle weights and CSA to the 
preliminary study in B6 mice.   
 No differences were seen between CON, CON Non-Ulcerated and CON 
Ulcerated with regards to EDL CT, SOL CT and SOL ½ RT (Figure 10A, 10C, 10D).  
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Figure 14 EDL Fatigue Curve for CON and TG:  A. EDL fatigue curve showing a significant shift in both the CON 
Non-Ulcerated and CON Ulcerated groups for the 20-80 second time points.  B. EDL fatigue tracing of the first 
100 seconds.  C.  EDL fatigue curve shows a significant shift in both the TG Non-Ulcerated and TG Ulcerated 
groups for the 40-70 second time points.  D.  EDL fatigue tracing of the first 100 seconds.  CON (n=8), CON Non 
(n=8), CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001 
 
EDL ½ RT did show a significant increase in the CON Non-Ulcerated groups.  In the TG 
groups, EDL CT and ½ RT both showed significant increases in the TG Non-Ulcerated 
and TG Ulcerated group (Figure 11E, 11F).  The SOL muscle showed no differences in 
either CT or ½ RT.  (Figure 11G, 11H).   
 
3.6 
Effects of IL-15 Skeletal Muscle Overexpression on Tetanic Force and Muscle 
Fatigue 
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Figure 15 EDL Area Under the Fatigue Curve A.  EDL Total Area Under the Fatigue Curve showed a significant reduction in the 
Con Non-Ulcerated group compared to CON.  B.  No statistical differences were seen between TG groups.  CON (n=8), 4WK 
Non (n=8), 4WK Ulc (n=2), TG (n=7), TG Non (n=8), 4WK (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001 
 
 
 EDL absolute force in the control group yielded a significant reduction of force 
production in the CON Non-Ulcerated and CON Ulcerated indicating a weaker muscle in 
the presence of cancer (Figure 12 A).  When looking at relative force however we see 
no shifts in the force curve, indicating these forces are producing normal tetanus for 
their relative frequency of stimulation (Figure 12 B).   EDL tetanus force did see a 
significant decrease in the CON Non-Ulcerated group (Figure 12 C).  These results may  
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Figure 16 SOL Fatigue Curve for CON and TG:  A. SOL fatigue curve showing a significant shift in in both the CON and 
the CON Ulcerated group compared to the CON Non-Ulcerated group. B. SOL fatigue tracing of the first 100 seconds.  
C. SOL fatigue curve showing no statistical differences between groups.  D. SOL fatigue tracing of the first 100 seconds. 
CON (n=8), CON Non (n=8), CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001 
 change when boosting the CON Ulcerated group.  EDL Absolute Tetanus Force in the 
TG groups saw a significant reduction in the TG Non-Ulcerated and TG Ulcerated 
groups compared to control (Figure 12 D).   When looking at relative Tetanus there is a 
slight significant shift at the 25-50Hz points for the TG Non-Ulcerate and TG Ulcerated 
(Figure 12 E).  EDL max tetanus however, shows no significant differences between the 
groups of TG mice (Figure 12 F).  SOL muscles in the control group yielded a significant 
decrease in absolute force frequency in the CON Non-Ulcerated and CON Ulcerated 
group when compared to the CON group at the 25Hz-100Hz stimulation frequency 
(Figure 13A).  Relative force frequency however, showed only a significant shift at the 
100Hz stimulation frequency CON Non-Ulcerated group and CON Ulcerated group 
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when comparing to the CON group (Figure 13B).   Interestingly, the CON Ulcerated 
group produced significantly less maximal tetanic force when compared to the CON 
group (Figure 13 C).  Transgenic SOL muscles showed a significant decrease in 
absolute force in both the TG Non-Ulcerated and TG Ulcerated group at the 80Hz-
100Hz stimulation frequencies (Figure 13 D).  Similar to the CON group, TG mice 
showed a significant shift in the relative force frequency at the 100Hz stimulation 
frequency in both the TG Non-Ulcerated and TG Ulcerated (Figure 13 E).  TG SOL 
muscles showed no statistical differences in maximal tetanus force between any of the 
groups.  The EDL fatigue tracing of the CON group showed a significant shift down and  
to the left in both the CON Non-Ulcerated and CON Ulcerated (20-80 seconds) 
indicating a significant amount of fatigue in these mice (Figure 14 A) similar to the 
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Figure 18 CON and TG Tumor Dissociation: No statistical differences were seen between B6 Tumor and 
TG Tumor, however there was an overall trend toward increased CD4 (helper) and CD8 (cytotoxic) T 
cells in the TG mice.  CON (n=8), CON Non (n=8), CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, 
**=P<0.005, ***=P<0.0001 
 
tracing seen in the B6 preliminary study (Figure 4 A).   EDL fatigue tracing in the TG 
group showed a significant shift down and to the left in the TG Non-Ulcerated and TG 
Ulcerated groups (40-70 seconds) however it was  a smaller shift in fatigue as well as a 
smaller duration indicating attenuation of fatigue in the EDL muscle (Figure 14 C).  EDL 
AUC measurements showed a significant reduction in area in the CON Non-Ulcerated 
group compared to the CON group Figure 15.  EDL TG AUC showed no differences 
between groups.  SOL fatigue curves for the CON group show a significant shift down 
and to the left in the CON and CON Ulcerated group (Figure 16 A).  This trend is not 
typical but perhaps came about because of the small number of mice in the CON 
Ulcerated group and the very large SD of the CON Non-Ulcerated group.  No 
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statistical differences were seen between the TG groups (Figure 16 C).  
3.7 
IVIS, Ultrasound, Tumor and Spleen cell isolation:  
Images were taken every week of both the bioluminescence of each tumor using IVIS 
imaging as well as the volume of each tumor measured by In Vevo Ultra sound.  These 
data showed no statistical differences in progression of tumor growth when comparing 
groups.  We did see an overall trend towards reduction of tumor size around the 2 week 
group, however this did not reach significance. After dissecting out whole tumors from 
mice, single cell suspensions were generated and stained looking for differences in T 
cell and NK cell populations.  No statistical differences were seen between B6 Tumor 
(n=3) of TG Tumor (n=5), however there was a trend toward increasing in the TG Tumor 
group which could be further vilified if the groups were increased (Figure 18).   When 
analyzing single cell suspension of the spleen from both CON vs CON Tumor and TG 
vs TG Tumor we saw a significant reduction in T Cell % in  both groups (Figure 19).  We 
did not see any other statistical differences in T Cell or NK Cell populations however in 
any of the spleen groups.  (Figure 19, 20) 
 
3.8 
Tumor/Mouse weight, Muscle/BW 
No differences were seen between either CON or TG groups with regard to tumor 
volume or weight (Figure 21 A and B).  Body mass was reduced significantly after 
removal of the tumor in both CON Non-Ulcerated and CON Ulcerated groups, however 
% change in body mass was not significant (Figure 21 C and D.)   
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Figure 19 Spleen Cell Dissociation CON and TG:  A. CON Tumor spleens showed a significant reduction in T 
cell % when compared to CON spleens.  B., C. No statistical differences were seen between CD4% or CD8 % 
between groups.  D.  TG Tumor spleens showed a significant reduction in T cell % when compared to TG 
spleens.  E., F. No statistical differences were seen between CD4% or CD8 % between groups CON (n=8), CON 
Non (n=8), CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001 
 
TG Non-Ulcerated mice showed a significant reduction in body mass once the tumor 
was removed compared to TG uninjected (Figure 21 G).  TA/BW showed a significant 
decrease in both the CON Non-Ulcerated and CON Ulcerated muscles when compared 
to CON muscles (Figure 22 A).  Both the Gastroc/BW and Quad/BW showed significant 
decreases in the CON Non-Ulcerated when compared to CON muscles (Figure 22 B, 
D).  Only TA/BW showed a significant decrease in both TG Non-Ulcerated and TG 
Ulcerated when compared to TG muscles (Figure 22 E). 
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Figure 20 Spleen Dissociation CON and TG: No statistical differences were seen between groups in 
NK or NKT cells following spleen dissociation.  CON (n=8), CON Non (n=8), CON Ulc (n=2), TG (n=7), TG 
Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001 
 
Figure 21 Tumor BW/Volume and Mouse Body mass:  A., B., E., F., No statistical differences were seen between 
tumor weight or tumor volume in either CON or TG groups.  C.  Body mass with tumor removed showed a 
significant decrease in both CON Non-Ulcerated and CON Ulcerated compared to CON.  G.  TG Non-Ulcerated body 
mass without tumor showed a significant decrease when compared to TG mice.  D., H. No statistical differences 
were seen between groups with regards to % difference in body mass. CON (n=8), CON Non (n=8), CON Ulc (n=2), 
TG (n=7), TG Non (n=8), TG Ulc (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001 
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Figure 22 Muscle Weights/BW in CON and TG mice:  A. TA/BW showed significant decreases in CON Non-
Ulcerated and CON Ulcerated muscles compared to CON muscles.  B.  Gastroc/BW showed a significant 
decrease in CON Non-Ulcerated compared to CON muscles.  C. No statistical differences were seen between 
Plantaris/BW.  D. Quadriceps/BW showed a significant decrease in the CON Non-Ulcerated compared to CON 
muscles.  E.  TA/BW showed significant decreases in TG Non-Ulcerated and TG Ulcerated muscles compared 
to TG muscles.  F., G., H. No statistical differences were seen between groups.  CON (n=8), CON Non (n=8), 
CON Ulc (n=2), TG (n=7), TG Non (n=8), TG Ulc  (n=4) *=P<0.05, **=P<0.005, ***=P<0.0001 
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Chapter 5 
General Discussion 
 Injection of the EO771 mammary tumor cell line into C57BL/6 mice has been 
show to induce significant muscle wasting and muscle fatigue.  This is verified by 
significant decreases in muscle weights as well as body weight, along with the 
increased fatigue shown at the 4-week post injection time point (Figure 2,4,7 and 8).  
Coinciding with the increased fatigue we showed a decreased mtDNA content (fold 
difference) in both 4-week time points suggesting these muscles are fatiguing more than 
the CON and 2WK due to less functional mitochondria.  Indeed, our lab has shown the 
opposite of this where there is an increased mtDNA content via increases in secretion of 
IL-15 (23,39).  In this model we also show a significant shift in the force frequency 
relationship in the EDL muscles of both 4WK Non-Ulcerated and Ulcerated 
groups(Figure 3 B) along with lower tetanus forces in both 4 week groups for both EDL 
and SOL.  This shows that these muscles are not only fatiguing more, but they are 
producing greater forces at lower stimulation frequencies indicating overall muscle 
dysfunction and a more fatigable phenotype.  Along with this we show significant 
increases in mRNA content for various biomarkers of atrophy (Murf1 and Atrogin1), 
inflammatory markers for cachexia (IL-6 and TNFα) and significant decreases in IL-15 
and IL-15 rα which have proposed mechanisms behind mitochondrial biogenesis 
(40,41).  We also show a significant shift in muscle fiber area in the EDL muscle after 
laminin staining in both the 4 week groups, supporting our claim that the muscles weight 
less and have a smaller CSA yielding less force and fatiguing at a more rapid rate than 
CON of 2WK mice.  Our flow cytometry data from our spleen cell isolation did not show 
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significant differences; however when comparing just the CON and 2WK groups we saw 
a significant decrease in T cell % (Figure 10).  The reasoning behind this notion is that 
the immune response generated by the cancer can be transient in the perspective of 
this study.  Indeed, with this timeframe (4 weeks) the tumor has had time to bypass the 
immune system and shed potential targeting antigens (31,32).  This could lend some 
insight as to why our deviations at the 4 week time points are so variable.  These data 
show that the EO771 cell line induces cancer cachexia and muscle dysfunction 
(fatigue), and furthermore is an ideal model to test our proposed therapy of IL-15 
skeletal muscle overexpression (Figure 5).     
 Previous work shows the ability of IL-15 to promote a pro-oxidative/fatigue 
resistant phenotype along with increasing overall mitochondrial density (38,40,41,53).  It 
is by this mechanism that we propose our therapy will prevent the muscular fatigue in 
our model.  With regards to muscle weights and CSA we saw similarities in the TG 
groups showing significant decreases in weight and CSA, coinciding with the 
preliminary study.  The littermate controls showed a similarities in the CON Non-
Ulcerated groups, however due to a small sample size (n=2) the CON Ulcerated group 
did not recapitulate the trend seen in our preliminary work (Figure 10).  Looking at the 
functionality of the EDL muscle, TG CT and ½ RT showed significant decreases in both 
TG Non-Ulcerated and Ulcerated groups signifying alterations in Ca+ handling due to 
the systemic effects of the cancer (Figure 11).  Again we did not see the same results 
represented in our CON groups, we believe this to be due to a small sample size.  EDL 
muscles from both the CON and TG groups showed a significant decrease in muscle 
mass in the Non-Ulcerated and Ulcerated groups for absolute force frequency (Figure 
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12).  This coincides with our previous study showing the EDL muscle producing less 
overall force in tumor bearing mice.  Looking at the relative force frequency curve 
however, we show no shift in the CON group indicating the muscles are not producing 
greater force at lower frequencies which would indicate dysfunction.  This is dissimilar to 
our preliminary study where, indeed we showed a significant shift in the force frequency 
curve.  Possible explanations could be attributed to the small sample size, along with 
the fact these mice may have not been as severe as our previous study with regards to 
tumor burden.  SOL muscles for both CON and TG showed a significant reduction in 
absolute force frequency similar to EDL muscles, however this was ablated when 
looking at relative force frequency.  These data highlight the ability of a more oxidative 
muscle, even in the absence of IL-15 overexpression (i.e. littermate control) to preserve 
overall function in the presence of cancer cachexia.  Of note, the SOL maximal tetanus 
contraction did show a significant decrease in the CON vs CON ulcerated group.  
 The major focus on this study was the attenuation of muscle fatigue in the 
presence of cancer cachexia.  Using our fatigue protocol, we saw a significant shift 
down and to the left in force produced throughout our fatigue curve (% force loss)  for 
both the CON Non-Ulcerated and CON Ulcerated mice vs CON (Figure 14).  This shift 
was significant for contractions between 20-70 seconds showing a much more rapid 
and prolonged fatigue.  In comparison, the TG fatigue curve showed a much smaller 
shift in Non-Ulcerated and Ulcerated mice, however still significant (Figure1 14).  Of 
note this fatigue curve started later in the protocol (40 seconds) highlighting the 
attenuation of fatigue.  It is important to note that these effects happened regardless of 
muscle mass loss, considering TG EDL muscles showed similar weight loss to our 
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preliminary study.  Another method of analysis was looking at the overall area under the 
fatigue curve.  We classify this as the total amount of force in mN throughout the 6 
minute fatigue protocol.  We see there was a significant reduction in area under the 
fatigue comparing the CON and CON Non-Ulcerated mice.  This reinforces the idea that 
there is an increased fatigue in these mice (Figure 15).  Again if we had more mice in 
the CON Ulcerated group we feel that we would have reached significance considering 
our preliminary study.  Looking at the TG area under the fatigue curve we show no 
differences between groups, further exemplifying the attenuation of fatigue in these 
mice (Figure 15).  These data suggest IL-15 has the ability to promote a fatigue 
resistant phenotype, attenuating overall fatigue experienced in cancer cachexia 
settings.  When looking at the more oxidative muscle (SOL) we saw no significant 
differences in relative fatigue between either CON for TG groups, again showing 
preservation of function in a more mitochondrial dense muscle (Figure 16).  
  When we imaged these mice we saw a slight trend towards overall reduction of 
size in tumors of the TG groups, however it was not significant.  IL-15 has been shown 
to promote overall immune function and cell cytotoxicity when treating cancer patients in 
clinical trials (54-56).  However, previous work with this cell line has shown that the 
immunosuppressive nature of EO771 tumors can make it a challenging model to test 
immune based therapies (57).  We showed a trend with reduction of tumor burden in the 
TG injected mice looking at tumor volume and IVIS bioluminescence, however there 
was no significance (Figure 17).  Furthermore, we showed no statistical differences 
between the CON Tumor and TG Tumor following dissociation looking at different 
immune cells (CD4 Helper T, CD8 Cytotoxic T, NK1.1, NKT) (Figure 18).  With the 
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spleen cell dissociation, we did show a significant reduction in T cells in the CON Tumor 
and TG Tumor when compared to their respective controls, however no other stains 
showed any significant differences (Figure 19 and 20).  We attribute this to the 
immunosuppressive nature of this tumor type (57) as well as the tumors ability at this 
point to bypass any immune response.  Further studies should be done looking at 
sooner time points (2WK) which would give us a better scope of the immune response 
with IL-15 treatment.  Looking at overall tumor burden (weight/volume) we did not show 
any statistical differences between Non-Ulcerated or Ulcerated groups for either CON or 
TG mice (Figure 21 A, B, E, F).  This could be a sample size issue considering the CON 
Ulcerated group had n=2 and the TG Ulcerated had N=4.  We did show that the body 
mass of CON mice with the tumor removed was significantly lower in the CON Non- 
Ulcerated and CON Ulcerated, along with a large difference in body mass in the CON 
Ulcerated groups, however not significant (Figure 21 C,D).  We did show a significant 
reduction in the TG Non-Ulcerated mass with tumor removed when compared to TG 
uninjected and we felt significance would be reached in the TG Ulcerated group if we 
increased the sample size (Figure 21).  Tibialis Anterior muscle dissection is the most 
accurate and precise dissection next to EDL and SOL muscles.  In the TA we showed 
significant reduction in CON Non-Ulcerated and CON Ulcerated weights compared to 
CON as well as significant reduction in TG Non-Ulcerated and TG Ulcerated compared 
to TG (Figure 22).  These data combine with our previous measurements show an 
overall decrease in muscle weight with the presence of cancer. 
 While we did not show differences in immune function, we were able to attenuate 
muscle fatigue in the presence of cancer due to IL-15 skeletal muscle overexpression.  
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These effects can be very translational due to IL-15 testing already taking place in 
clinical trials for improving immune function in cancer patients (7,54-56).  With this in 
mind IL-15 can be proposed as an effective dual immune/fatigue therapy by primarily 
targeting improvements in immune function all while attenuation skeletal muscle fatigue 
seen in cancer cachexia patients.  This becomes crucial when treatment of the cancer 
takes place.  With chemotherapy potentially exacerbating cachexia, the ability to 
attenuate fatigue and improve immune response will likely lead to a faster recovery and 
decreased morbidity and mortality.   
 The next step for this project would be the addition of mice to both 4WK 
Ulcerated groups.  This would give us an overall even number in each group, potentially 
allowing our littermate control data to recapitulate our preliminary research.  Additionally 
we plan to dissociate more tumors in the 4WK groups, as well as establishing a 1 and 2 
week time point.  We feel the addition of these groups will potentially lead to our further 
understanding of the effects IL-15 has in the immune response in our particular model. 
 Our next proposed step would be the administration of IL-15 via osmotic mini 
pump.  After a preliminary trial using an IL-15 administered group (n=2) and a sham 
groups given sterile PBS (n=2) we were able to perform a sterile surgery and have mice 
survive to the 4 week time point.  Moving forward we plan to repeat the protocol both 
addressing different dose dependent alterations in muscle function and immune cell 
populations, but also identifying any toxic or inflammatory responses associated with 
this method of administration.  Indeed, previous work in cancer patients who were 
administered human IL-15 showed positive responses in CD8 T cell and NK cell activity.  
Higher doses however, were also associated with increased toxicity and a larger 
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inflammatory response (55).  This will allow us to identify a dose that will produce the 
best response in attenuating muscle fatigue.  Following this we can scale up dosing to 
address muscle fatigue in a clinical setting of cancer cachexia 
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Chapter 5  
 
Methodology 
6.1 
Mice 
C57BL6WT mice were purchased from The Jackson Laboratory (n=23) and randomly 
assigned to a control group (Control; n=8), mice that were euthanized following 2 weeks 
of tumor growth (2WK, n=5), and mice that were euthanized following 4 weeks of tumor 
growth (4WK, n=10).  The 4WK group was subsequently divided into mice that 
developed an ulcerated tumor (4WK-UT; n=6) and mice that developed a non-ulcerated 
tumor (4WK-NUT; n=4).  IL-15 TG muscle overexpressor mice were purchased from 
Jackson Laboratory and bred yielding IL-15 TG overexpressor pups and littermate 
controls, which were used for the subsequent experiment.  Mice were split into six 
groups; a control uninjected group (CON=8), a control Ulcerated group (CON Non-
Ulcerated=8), a Control Ulcerated group (CON Ulcerated= 2), a transgenic group 
(TG=7), a transgenic Non-Ulcerated group (TG Non-Ulcerated=7) and  transgenic 
Ulcerated group (TG Ulcerated=4)   Mice were housed in the animal vivarium at West 
Virginia University at 22°C under a 12:12-h light-dark cycle and received food and water 
ab libitum.  All animal experiments were approved by the Institutional Animal Care and 
Use Committee at West Virginia University. 
 
6.2 
E0771 Murine Breast Cancer Cells 
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The E0771 cell line used in these studies was kindly provided by Linda Metheney-
Barlow (Wake Forest)  E0771 cells were cultured using aseptic technique and 
maintained under standard mammalian culture conditions (37ºC, 99% humidity, 5% 
CO2).  Cells were maintained in high glucose DMEM supplemented with 10% FBS to 
maintain active proliferation.  Cells were passed via trypsinization using 0.25% 
trypsin/EDTA in Hanks buffered saline solution (Gibco).   Cells were grown until ~90% 
confluent at which time they were prepped for injection.  Cells were trypsinized and 
resuspended in sterile PBS.   A cell count was performed yielding 1 million cells per 
100µL injection into the 4th nipple (mammary fat pad) of female C57BL6WT mice and 
IL-15 TG mice.   
 
 
6.3 
Muscle Physiology on EDL and SOL Muscle in C57BL6WT mice and IL-15 TG 
overexpression mice. 
 Female mice were deeply anesthetized by breathing 4% isoflurane delivered through a 
nose cone at a flow rate of 1 l/min. Muscles were removed with both proximal and distal 
tendons intact, and nylon sutures were attached to the tendons. Muscles were 
transferred to an oxygenated tissue bath that contained Ringer solution (100 mM NaCl, 
4.7 mM KCl, 3.4 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, and 
5.5 mM D-glucose) maintained at 22°C. Ex vivo muscle stimulation was performed 
using a commercially available muscle physiology system (Aurora Scientific, Ontario, 
CA). Muscle length was adjusted to obtain the maximal twitch response (i.e., Lo). Three 
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twitch contractions were performed all separated by 2 min. Parameters analyzed from 
isometric contractions included peak isometric twitch force (Pt), time to peak twitch 
tension (TPT), half-relaxation time of twitch contraction (½ RT), and peak isometric 
tetanic force (Po).  Isometric tetanic contractions were stimulated in muscles at a 
stimulation frequency of 120 Hz for EDL muscles and 80 Hz for soleus muscles, a 
stimulation current of 20 V, and lasting 500 ms.   Following isometric contractions, the 
muscles remained in oxygenated Ringer’s for 5 minutes prior to the repeated-
stimulation fatigue protocol. Muscle fatigue was analyzed using a repeated stimulation 
protocol lasting 6 min and consisting of repeated 40-Hz tetanic trains that occurred once 
every second and lasted 330 ms.   
 
6.4 
Muscle Morphology  
Due to our previous reports showing a decrease in fiber area with progression of cancer 
cachexia EDL and SOL muscles will be flash frozen in isopentane cooled to the 
temperature of liquid nitrogen and stored at –80°C.   Serial frozen sections (10 μm thick) 
of EDL and SOL muscles were obtained using a cryostat at −21°C and placed onto 
glass slides (Superfrost/Plus, Fisher Scientific). Sections were stained with Alexa 
Flour® 488-conjugate AffiniPure Goat Anti-Rabbit IgG (Jackson ImmunoResearch 
Labratories, INC) and ANTI-LAMININ Affinity Isolated Antigen Specific 
Antibody(SIGMA-ALDRICH®) and then mounted with 4’,6-diamidino-2-phenylindole 
(DAPI) mounting medium (Vector Laboratories, Burlingham, CA).  Similar Analysis will 
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be performed using the Image Process & Analysis Workstation in the CORES Facility, 
utilizing the Muscle Fiber General Analysis protocol. 
 
6.5 
Mitochondrial DNA content 
Total DNA (genomic and mitochondrial) will be extracted from tibialis anterior (TA) 
muscles from female mice using a DNeasy Blood and Tissue kit (Qiagen, Valencia, CA) 
and quantified using a Nano-Drop spectrophotometer (ThermoScientific, Waltham, MA). 
TaqMan primers for mitochondrial DNA-encoded cytochrome-c oxidase subunit II 
(COXII) and nuclear-encoded 18S ribosomal RNA will be used to perform real-time 
qPCR. The wells of a 96-well optical reaction plate were loaded with a 20-μl volume 
consisting of TaqMan 10X PCR Master Mix, a primer mix for either the mitochondrial-
encoded gene or the nuclear-encoded gene, and DNA diluted to a concentration of 5 
ng/μl. Each DNA sample was analyzed in pairs and amplified in an Applied Biosystems 
7900HT Fast Real-Time PCR system. The cycle threshold (CT) values of the 
mitochondrial-encoded COXII gene and the nuclear-encoded 18S gene in muscles 
C57BL6 WT mice were used to quantify the fold change using the ΔΔCT calculation 
(58) 
 
6.6 
RNA Isolation and PCR 
Total RNA will be isolated using Trizol reagent (Life Technologies, Grand Island, NY), 
as  previously described (59). RNA quantity and quality will be assessed using a Nano-
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Drop 2000 spectrophotometer (ThermoScientific, Waltham, MA); the 260/280 ratio for 
all samples used was between 1.8 and 2.1. Two micrograms of total RNA will be 
reverse transcribed to make cDNA using a high-capacity reverse transcription kit 
according to manufacturer's instructions (Life Technologies, Grand Island, NY).  
Amplification was performed in a reaction consisting of 8.5 μl nuclease-free H2O, 12.5 
μl 2X Taq-Pro Red Complete 1.5 mM MgCl2 master mix (Denville Scientific, Metuchen, 
NJ), 1.0 μl forward primer, 1.0 μl reverse primer, and 2 μl of DNA template to make a 25 
μl total reaction volume. Primers were constructed from published sequences.   Primer 
pairs for IL-15, IL-15 rα, IL-6, TNFα, Grim19, Murf1 and Atrogin-1 were coamplified with 
primer pairs for 18S (Ambion, Austin, TX). The number of PCR cycles was determined 
in preliminary experiments to ensure analyses were done in the linear range of 
amplification. Following amplification, each reaction will be visualized following gel 
electrophoresis in 1% (wt/vol) agarose gels stained with ethidium bromide.  PCR bands 
were quantified using the ImageJ software program (http://rsbweb.nih.gov/ij/). Signals 
for the gene of interest were normalized to the bands for 18S that were amplified in the 
same reaction.   
 
6.7 
Spleen Cell Isolation  
Single cell suspensions from the spleen and of each mouse were extracted and a single 
cell suspension  of 1 million cells will be generated following cell isolation, red blood cell 
lysing and washing steps (1.5% FBS RPMI). Staining will comprise of CD3 (generalized 
T cell marker), CD4 (Helper T cell marker), CD8 (Cytotoxic T cell) and Natural Killer cell 
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staining (NK).  T cell count will be gated to a CD45 cell surface marker antibody.   Flow 
data gives us a representative image of the percent of cells in solution.    
 
6.8 
Tumor Dissociation 
Tumors will be dissected away from mice and homogenized using the MACS tissue 
dissociator.  (MACS Miltenyi Biotec).  Following dissociation cells will be strained and 
the red blood cells with be lysed.  Following a period of wash steps similar to the spleen 
cell isolation, 1 million cells will be collected and stained for flow cytometry.  Staining will 
comprise of CD3 (generalized T cell marker), CD4 (Helper T cell marker), CD8 
(Cytotoxic T cell) and Natural Killer cell staining (NK).  T cell count will be gated to a 
CD45 cell surface marker antibody.   Flow data will give us a representative image of 
the percent of cells in solution.    
 
6.9 
IVIS Imagine and Tumor Burden 
Imaging of each mouse will take place once a week in the Animal Facility.  A luciferase 
injection will be administered so the EO771 cells illuminate during recording. Mice will 
be anesthetized by breathing 4% isoflurane delivered through a nose cone at a flow rate 
of 1 l/min. The subsequent images generated from this will be analyzed looking at tumor 
growth and total flux score.   
 
6.10 
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VEVO Tumor Volume 
Following IVIS Imaging, mice will be transferred to the VEVO Ultrasound room.   
Mice will be anesthetized by breathing 4% isoflurane delivered through a nose cone at a 
flow rate of 1 l/min.  Tumor volume will be measured using ultrasound (Visual Sonics) 
and tumor volumes calculated from these data. 
 
6.11 
Data Collection 
Statistical analysis was performed using GraphPad Prism 5 software.  Data will be 
reported as mean ± SEM, using ANOVA statistical analysis between experimental 
groups and student t-test where applicable.   
 
6.12 
Animal Care 
Mice were housed in the Animal Resources Department of West Virginia University 
School of Medicine in compliance with the NIH and the Institutional Animal Care and 
Use Committee guidelines.  Animals are attended by a full-time veterinary and support 
staff.  Unless noted otherwise, the animals are house in a pathogen-free environment, 
receive food and water ad libitum, and receive standard care daily.   
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Chapter 8 
Supplemental Data 
 
 
 
 
 
 
 
 
 
Supplemental 1 EDL and SOL Fiber Distribution: A.  EDL CON Fiber Area showed a shift in both 
the CON Non-Ulcerated and CON Ulcerated groups compared to CON muscles.  B. No 
differences were seen in SOL CON Fiber Area.  C. No differences were seen in the EDL TG Fiber 
Area.  D. No differences were seen in the SOL TG Fiber Area 
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 Supplemental 2:  A.  EDL absolute mass showing significant decreases in both 4 week groups compared to 
CON and 2WK,  ELD mass normalized to body mass without the tumor showed significant decreases in both 
4 week groups compared to CON mice.  B.  Absolute Soleus mass showed significant decreases in the 4 
week Ulcerated groups compared to CON.  C.  TA absolute mass showed significant decreases in both 4 
week groups compared to CON and 2 week,  TA mass normalized to body mass without the tumor showed 
significant decreases in both 4 week groups compared to CON and 2 week.  D.  Gastrocnemius absolute 
mass showed significant decreases in both 4 week groups compared to CON and 2 week.  E.  Hear mass 
normalized to body mass without the tumor showed a significant increase in 4 week ulcerated mass 
compared to CON and 2 week.  F.  Both Absolute and normalized to body mass without the tumor weights 
of the spellen showed significant increases  in the 4 week groups compared to the CON and 2 week groups 
